Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001229581 | SCV001402032 | uncertain significance | Bardet-Biedl syndrome | 2021-08-28 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine with tryptophan at codon 686 of the BBS2 protein (p.Arg686Trp). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and tryptophan. This variant is present in population databases (rs372135700, ExAC 0.02%). This variant has not been reported in the literature in individuals affected with BBS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002484252 | SCV002787598 | uncertain significance | Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 | 2022-02-12 | criteria provided, single submitter | clinical testing | |
Preventiongenetics, |
RCV003398982 | SCV004120273 | uncertain significance | BBS2-related condition | 2022-10-05 | criteria provided, single submitter | clinical testing | The BBS2 c.2056C>T variant is predicted to result in the amino acid substitution p.Arg686Trp. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.012% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-56519505-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Natera, |
RCV001828836 | SCV002089251 | uncertain significance | Bardet-Biedl syndrome 2 | 2021-08-23 | no assertion criteria provided | clinical testing |